Background and objectives: Incomplete distal renal tubular acidosis is a well-known cause of calcareous nephrolithiasis but the prevalence is unknown, mostly due to lack of accepted diagnostic tests and criteria. The ammonium chloride test is considered as gold standard for the diagnosis of incomplete distal renal tubular acidosis, but the furosemide/fludrocortisone test was recently proposed as an alternative. Due to the lack of rigorous comparative studies, the validity of the furosemide/fludrocortisone test in stone formers remains unknown. In addition, the performance of conventional, non-provocative parameters in predicting incomplete distal renal tubular acidosis has not been studied. Design, setting, participants, and measurements: We conducted a prospective study in an unselected cohort of 170 stone formers that underwent sequential ammonium chloride and furosemide/fludrocortisone testing. Results: Using the ammonium chloride test as gold standard, the prevalence of incomplete distal renal tubular acidosis was 7.78 %. Sensitivity and specificity of the furosemide/fludrocortisone test FF test were 77 % and 85 %, respectively, yielding a positive predictive value of 30 % and a negative predictive value of 98 %. Testing of several non-provocative clinical parameters in the prediction of incomplete distal renal tubular acidosis revealed fasting morning urinary pH and plasma potassium as the most discriminative parameters. The combination of a fasting morning urinary threshold pH <5.3 with a plasma potassium threshold >3.8 mmolmEq/l yielded a negative predictive value of 98 % with a sensitivity of 85 % and a specificity of 77 % for the diagnosis of incomplete distal renal tubular acidosis. Conclusions: The furosemide/fludrocortisone test can be used for incomplete distal renal tubular acidosis screening in stone formers, but an abnormal furosemide/fludrocortisone test result needs confirmation by ammonium chloride testing. Our data furthermore indicate that incomplete distal renal tubular acidosis can reliably be excluded in stone formers by use of non-provocative clinical parameters. 
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INTRODUCTION
Incomplete distal renal tubular acidosis (dRTA) is a condition characterized by defective urinary acidification capacity in the absence of systemic metabolic acidosis. The entity was first described by Wrong and Davies in 1959 who reported 3 patients that were unable to maximally acidify their urine upon administration of an oral acid load (100 mg [1.86 mmol] ammonium chloride/kg body weight) 1 . Based on this study the one day single dose ("short") ammonium chloride loading test became the "gold standard" for diagnosis 1 . Typically, a pH < 5.3 has been accepted as threshold to rule out dRTA but there has never been a clear consensus on this threshold pH and various other definitions have been employed in the past [2] [3] [4] [5] [6] [7] [8] . Using non-uniform definitions and provocative test procedures, a wide range of prevalence of incomplete dRTA from 2 to 21 % have been reported in recurrent stone formers 3, 9, 10 .
Provocative urinary acidification testing is not routinely conducted at most stone clinics but most clinics have routine clinical data on their patients with nephrolithiasis. How well do conventional non-provocative clinical parameters perform in the prediction of incomplete dRTA is not known and previous recommendations have been based primarily on expert opinions rather than data 10, 11 . Even when the short ammonium chloride loading test can be performed in some centers, gastrointestinal side effects occur frequently after ammonium chloride ingestion. In 2007, Walsh et al. described an alternative provocation of distal acidification, the furosemide/fludrocortisone test, which is better tolerated than the ammonium chloride loading test 12 . In a study that included 10 patients with nephrolithiasis or nephrocalcinosis (all without dRTA), Viljoen et al. observed a high false positive rate of incomplete dRTA diagnosis with the furosemide/fludrocortisone test compared to the gold standard ammonium chloride test, but fludrocortisone was given 10 h prior to test start and not simultaneously, as described by Walsh et al. 12, 13 . Thus, due to the current lack of To address the issues outlined above, we compared clinical non-provocative parameters and the furosemide/fludrocortisone test results to the standard short ammonium chloride test in an unselected group of stone formers referred to our clinic for metabolic stone work-up. 
MATERIALS AND METHODS

Study design and study population
This was a prospective comparative study. Study participants were recruited from stone formers referred to the Division of Nephrology and Hypertension at the Bern University Hospital between September 2012 and June 2016. Inclusion criteria were: i) ≥ 1 kidney stone episodes, ii) age ≥ 18 and iii) written informed consent. Exclusion criteria were: i) active urinary tract infection, ii) intake of medications known to interfere with urinary acidification, iii) pregnancy or lactation. Failure to acidify urinary pH < 5.3 in the ammonium chloride test was considered diagnostic for incomplete dRTA diagnosis. Complete dRTA was defined as presence of a pathological urinary acidification test with a concomitant metabolic acidosis in the morning fasting blood gas analysis (blood pH < 7.35 and blood bicarbonate < 21 mEq/l).
Patients with an abnormal urinary acidification test without metabolic acidosis were considered to have incomplete dRTA. No sample size calculation was performed before start of the study because i) the prevalence of idRTA in our referred patients was not known and ii) absence of data with respect to the performance of the furosemide/fludrocortisone test in the diagnosis of idRTA in an unselected cohort of stone formers. The study was approved by the Ethical Committee of the Kanton Bern (approval # 90/12), registered at ClinicalTrials.gov (NCT01690039) and conducted in accordance with the Declaration of Helsinki.
Data collection and measurements
Metabolic work-up for stone disease included two 24 h urines on a random outpatient diet.
Urine and blood analyses were performed at the Central Laboratory of the University Hospital of Bern, Switzerland using standard laboratory methods. Urine pH in 24 h urines was measured by a S20 SevenEasy pH meter (Mettler Toledo, Greifensee, Switzerland). Estimated glomerular filtration rate (eGFR) was calculated according to CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) [28] . Diabetes was defined as reported, treated, fasting glycemia ≥126 mg/dl, or random glycemia ≥200 mg/dl. Hypertension was defined as reported, treated, a mean systolic blood pressure ≥140 mmHg, or a mean diastolic blood pressure ≥90 mmHg.
Ammonium chloride and furosemide/fludrocortisone tests
All participants underwent sequential ammonium chloride and furosemide/fludrocortisone testing, at least 1 week and at most 1 month apart, regardless of 24 h or fasting urinary pH or type of stone, thereby constituting a completely unselected population of calcareous stone formers. The short one day ammonium chloride loading test and the furosemide/fludrocortisone test were performed as previously described 1, 12 . Study participants fasted after midnight and throughout the tests. For the ammonium chloride test, ammonium chloride gelatin capsules (100 mg/kg body weight) were given at 0800 h with water in the presence of the nursing staff over a period of 30 minutes. During the test, fluid intake was ad libitum. Venous blood samples were obtained for chemistry, pH and blood gases at 0800, 1000, 1200 h. Urine was collected hourly from 0800 to 1400 h. For the furosemide/fludrocortisone test, furosemide (40 mg) and fludrocortisone (1 mg) were given at 0800 h with water in the presence of the nursing staff. During the test, fluid intake was ad libitum. Venous blood samples were obtained for chemistry, pH and blood gases at 0800, 1100, 1300 h. Urine was collected hourly from 0800 to 1300 h. Venous blood gas and electrolyte analysis was performed immediately after collection on a ABL800FLEX blood gas analyzer (Radiometer, Thalwil, Switzerland). Urine pH was measured by a S20 SevenEasy pH meter and urinary pCO 2 by an ABL700 blood gas analyzer (Radiometer, Thalwil, Switzerland) immediately after collection. Statistical analyses were conducted using the R software, version 3.2.2 14 . All statistical tests were two-sided and a p value <0.05 was considered as statistically significant. Agreement between the two urinary acidification tests was analyzed by the Bland-Altman method using the R package "BlandAltmanLeh" 15 . ROC analysis was done using the R package "pROC" 16 . The sensitivity-specificity versus nadir urinary pH plot (Fig. 1F ) was done by using the R package "OptimalCutpoints" 17 . The associations of the nadir urinary pH with 24 h citraturia and with calciuria were visually assessed by cubic spline functions of the nadir urinary pH and by boxplots stratifying the nadir urinary pH at different thresholds. 
Statistical analysis
RESULTS
Characteristics of study population
Two of the 170 individuals recruited had complete dRTA and were excluded from the final analysis. Baseline characteristics of the remaining 168 participants are depicted in Table 1 .
Median age of the study population was 45 years, 73 % of participants were men. The majority of individuals (76 %) had ≥ 2 symptomatic stone events, stone analysis was available in 83 % of individuals. Baseline blood and urinary biochemistries are depicted in Suppl. Table 1 .
Phenotype of stone formers according to nadir urinary pH
Thirteen participants (8 %) in the ammonium chloride test and 33 participants (20 %) in the furosemide/fludrocortisone test had a nadir urinary pH ≥ 5.3. Baseline characteristics of stone formers, listed separately by test and nadir urinary pH are depicted in Table 2 . Stone formers with nadir urinary pH ≥ 5.3 in the ammonium chloride test had a lower BMI (p=0.02). Kidney stones of participants with nadir urinary pH ≥ 5.3 in both test were less likely to contain calcium oxalate but more likely to contain calcium phosphate. None of the stones of participants with nadir urinary pH ≥ 5.3 contained uric acid. Stone formers with nadir urinary pH ≥ 5.3 in the ammonium chloride test displayed a significantly lower plasma potassium and 24 h citrate excretion, while 24 h urea excretion (a measure of daily protein intake), net gastrointestinal alkali absorption (an arithmetic estimate of daily alkali intake) and kidney function were similar in subjects with nadir urinary pH <5.3 or ≥ 5.3 ( Table 3) 18 .
How well do non-provocative parameters perform in predicting incomplete dRTA ?
To this end, we tested the performance of the non-provocative parameters morning fasting urinary pH, plasma potassium, plasma bicarbonate, 24 h citraturia and stone calcium Fig. 1 ). Receiver operating characteristic (ROC) analysis revealed that a second morning fasting urinary pH and plasma potassium had the highest individual area under the curve (AUC) for the prediction of incomplete dRTA, and a combination of the two parameters -second fasting morning urinary pH and plasma potassium -further increased the AUC (Suppl. Fig. 2 ).
Combination of a fasting morning urinary threshold pH of <5.3 and a plasma potassium threshold of >3.8 mmol/l yielded a negative predictive value of 98 % and a positive predictive value of 24 % for the diagnosis of incomplete dRTA ( Table 4 A). Use of higher urinary pH threshold caused a significant decrease of specificity, use of a higher plasma potassium thresholds resulted in significantly lower negative predictive values (not shown).
Performance of the FF test in the diagnosis of incomplete dRTA in stone formers
Utilizing the ammonium chloride test as gold standard, sensitivity and specificity of the furosemide/fludrocortisone test were 77 % and 85 %, respectively, yielding a positive predictive value of 30 % and a negative predictive value of 98 % for the diagnosis of dRTA, respectively ( Table 4 B (Fig. 1 C) . The absolute mean-difference plot (Bland- Altman plot) for the two tests is depicted in Fig. 1 D. The mean bias was +0.025 pH units, the lower and upper limits of agreement were -0.87 and 0.92, respectively and contained 160 of the 168 data points (95 %), as expected in case of a normal distribution 19, 20 . There was a (Fig. 1 E) . The sensitivity-specificity versus nadir urinary pH plot analysis yielded an optimal threshold nadir urinary pH of 5.19 for the furosemide/fludrocortisone test at a sensitivity and specificity threshold of 85 % and 81 %, respectively, which is close to the currently employed threshold urinary pH < 5.3 (Fig. 1 F) .
Pooled urine and blood analytes, separated by test and nadir urinary pH are depicted in Figs. 2   and 3 , respectively. Consistent with previous reports 1, 12 , we observed that the nadir urinary pH was achieved at ~3 h in the furosemide/fludrocortisone test and at ~5 h in the ammonium chloride test (Figs. 2 A, F) . As shown in Fig. 2 B-E, participants with a nadir urinary pH ≥ 5.3 in the ammonium chloride test displayed lower hourly urinary sodium, chloride and ammonium excretions while the urinary volume was unaltered. In the furosemide/fludrocortisone test participants with a nadir urinary pH ≥ 5.3 also displayed reduced hourly urinary sodium and chloride excretions, but only in the second half of the furosemide/fludrocortisone test (Figs. 2 H, I ). In contrast, urinary ammonium excretions in the furosemide/fludrocortisone test were similar in both groups of patients (Fig. 2 J) and urinary volumes were higher in participants with a nadir urinary pH ≥ 5.3 (Fig. 2 G) .
As expected, the administration of ammonium chloride resulted in a large decrease of venous pH and bicarbonate compared to baseline (systemic acid load) (Figs. 3 A, B) , whereas the administration of furosemide and fludrocortisone caused a small increase of venous pH and bicarbonate compared to baseline (increase of urinary acid excretion) (Figs. 3 C, D) . During the ammonium chloride and furosemide/fludrocortisone tests, venous pH was not significantly different between participants with nadir urinary pH < 5.3 and ≥ 5.3 at all time points measured. However, venous bicarbonate was significantly higher at baseline and at 4 h during the ammonium chloride test in participants with nadir urinary pH ≥ 5.3 (Figs. 3 A, B) .
In contrast, venous pH and bicarbonate were not different between participants with nadir Our results indicate that urinary acidification capacity is a continuous trait in stone formers. In addition to alkaline urinary pH, hypocitraturia and hypercalciuria are important prolithogenic factors frequently encountered in dRTA patients. As the next step, we analyzed the association of the nadir urinary pH in the ammonium chloride test with 24 h calciuria or 24 h citraturia. As shown in Figs. 4 A and C, with increasing nadir urinary pH, citrate excretion decreased and calcium excretion increased. Using the established pH < 5.3 for diagnosis, citraturia was significantly lower in participants with incomplete dRTA (Fig. 4 B) . However, 24 h calciuria was not different between participants with and without incomplete dRTA at this pH threshold (Fig. 4 D) . We next performed these analyses at different arbitrarily defined urinary nadir pH thresholds ranging from pH 5.1 to 5.5. As shown in Suppl. Fig. 3 , a pH < 5.3 was the only threshold pH which allowed a separation of the two groups of participants on the basis of citraturia. In contrast, at all pH thresholds tested, calciuria was not different between the two groups of participants. 
DISCUSSION
This is the first controlled study that rigorously compared the performance of the furosemide/fludrocortisone test and non-provocative parameters with the gold standard ammonium chloride test for the diagnosis of incomplete dRTA in stone formers. One important feature of this study compared to previous studies is the fact that we recruited stone formers without preselection into study, i.e. regardless of fasting or 24 h urinary pH, stone type or presence of hypocitraturia or hypercalciuria. The use of unselected patient population renders our results applicable to general kidney stone practices. The results of our study suggest that incomplete dRTA can be reliably excluded by use of the non-provocative parameters which includes second morning fasting urinary pH and plasma potassium. If a provocative test is required, the furosemide/fludrocortisone test has excellent negative predictive value. If incomplete dRTA cannot be excluded by either approach, the diagnosis can then be confirmed by ammonium chloride testing. Similar results were obtained with the ammonium chloride test, but the difference did not quite reach statistical significance. In contrast, uric acid calculi, typically associated with low urinary pH, were not observed at all in stone formers with incomplete dRTA defined by either tests 21 . This finding corroborates with previous studies that reported an association of a urinary acidification deficit with calcium phosphate-containing stones [22] [23] [24] . Interestingly, plasma potassium and 24 h citraturia were lower in stone formers with incomplete dRTA. The lower plasma potassium may at least partially explain the reduction in citraturia via a reduction of proximal tubular pH which is well known in potassium deficiency 25 . The pathogenesis and etiology of the reduced plasma potassium remains unclear, 24 h urinary excretions of sodium and potassium were similar in both groups of patients. Our surprising observation that stone formers with incomplete dRTA had a higher venous bicarbonate stands in contradiction to a recent study that reported results of urinary acidification testing in 57 individuals with primary Sjögren's syndrome 26 . Patients with primary Sjögren's syndrome and incomplete dRTA had lower venous pH and bicarbonate compared to patients with primary Sjögren's syndrome without incomplete dRTA, but higher venous pH and bicarbonate compared to patients with primary Sjögren's syndrome and complete dRTA. Although confirmation by longer term studies in primary Sjögren's syndrome patients is lacking, such a constellation would be compatible with incomplete dRTA being a "pre-acidotic" forme fruste of complete dRTA. In contrast, our finding of an increased venous bicarbonate in individuals with incomplete dRTA suggests that the underlying pathophysiology in stone formers maybe different, as suggested previously 27 . Importantly, our study reveals for the first time that urinary acidification capacity is not a dichotomous but a continuous trait in stone formers. This observation stands in contrast to the initial description by Wrong and Davies and the currently held opinion that incomplete dRTA represents a distinct entity with respect to urinary acidification capacity. Based on urinary citrate excretion, but not based on urinary acidification capacity or calcium excretion, a threshold pH < 5.3 can be justified for the diagnosis of incomplete dRTA.
There are no randomized controlled trials in stone formers with incomplete dRTA. In small studies, treatment with alkali in adult stone formers with incomplete dRTA decreased hypercalciuria, increased citraturia and reduced stone formation [28] [29] [30] . In stone formers with incomplete dRTA associated with medullary sponge kidney, alkali therapy also led to a decrease in stone passage and improvement of the associated bone disease [31] [32] [33] . Results of these uncontrolled studies indicate that stone formers with incomplete dRTA constitute a unique subset of patients that may benefit from alkali treatment. However, alkali treatment was also effective in the prevention of recurrence in unselected cohorts of patients with calcareous nephrolithiasis 34 . 
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